FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

FDA Approves First Drug to Treat Dementia-Associated Agitation in AD Patients

REXULTI® (brexpiprazole), Agitation associated with dementia due to Alzheimer's disease

FDA approves supplemental new drug application for Rexulti to treat Alzheimer's agitation

Rexulti On Track To Add Claim For Alzheimer's Dementia Agitation Following US Panel Nod :: Pink Sheet

Decision on Brexpiprazole for Alzheimer's Agitation Due in May

Why REXULTI® (brexpiprazole) agitation that may happen with dementia due to Alzheimer's disease

FDA Approves First Drug for Alzheimer's-Related Agitation Symptoms

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

REXULTI® (brexpiprazole) agitation that may happen with dementia due to Alzheimer's disease

Rexulti backed for Alzheimer's agitation by FDA adcomm